EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial

Liangbo Linus Shen, Jeremy D Keenan, Noor Chahal, Abu Tahir Taha, Jasmeet Saroya, Chu Jian Ma, Mengyuan Sun, Daphne Yang, Catherine Psaras, Jacquelyn Callander, Christina Flaxel, Amani A Fawzi und 11 weitere

Ophthalmology Science · 2024-05 · 4 (3) · 100440

DOI: 10.1016/j.xops.2023.100440 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Science, 2024-05. Verfasst von Liangbo Linus Shen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of California, San Francisco, San Francisco, California. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Research to Prevent Blindness.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Metformin use has been associated with a decreased risk of age-related macular degeneration (AMD) progression in observational studies. We aimed to evaluate the efficacy of oral metformin for slowing geographic atrophy (GA) progression.

Design

Parallel-group, multicenter, randomized phase II clinical trial.

Participants

Participants aged ≥ 55 years without diabetes who had GA from atrophic AMD in ≥ 1 eye.

Methods

We enrolled participants across 12 clinical centers and randomized participants in a 1:1 ratio to receive oral metformin (2000 mg daily) or observation for 18 months. Fundus autofluorescence imaging was obtained at baseline and every 6 months. Main Outcome Measures: The primary efficacy endpoint was the annualized enlargement rate of the square root-transformed GA area. Secondary endpoints included best-corrected visual acuity (BCVA) and low luminance visual acuity (LLVA) at each visit.

Results

Of 66 enrolled participants, 34 (57 eyes) were randomized to the observation group and 32 (53 eyes) were randomized to the treatment group. The median follow-up duration was 13.9 and 12.6 months in the observation and metformin groups, respectively. The mean ± standard error annualized enlargement rate of square root transformed GA area was 0.35 ± 0.04 mm/year in the observation group and 0.42 ± 0.04 mm/year in the treatment group (risk difference = 0.07 mm/year, 95% confidence interval = -0.05 to 0.18 mm/year; P = 0.26). The mean ± standard error decline in BCVA was 4.8 ± 1.7 letters/year in the observation group and 3.4 ± 1.1 letters/year in the treatment group (P = 0.56). The mean ± standard error decline in LLVA was 7.3 ± 2.5 letters/year in the observation group and 0.8 ± 2.2 letters/year in the treatment group (P = 0.06). Fourteen participants in the metformin group experienced nonserious adverse events related to metformin, with gastrointestinal side effects as the most common. No serious adverse events were attributed to metformin.

Conclusions

The results of this trial as conducted do not support oral metformin having effects on reducing the progression of GA. Additional placebo-controlled trials are needed to explore the role of metformin for AMD, especially for earlier stages of the disease. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

Stichwörter der Autor:innen

Age-related macular degenerationGeographic atrophyMetforminRandomized controlled trial

Autor:innen und Institutionen

  • Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
  • Francis I. Proctor Foundation for Research in Ophthalmology, University of California, San Francisco, San Francisco, California.
  • Institute of Cardiovascular Diseases, Gladstone Institute, San Francisco, California.
  • Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, California.
  • Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
  • Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Förderung

  • NEI NIH HHS
  • Research to Prevent Blindness

Zitieren

APA

Shen, L. L., Keenan, J. D., Chahal, N., Taha, A. T., Saroya, J., Ma, C. J., Sun, M., Yang, D., Psaras, C., Callander, J., Flaxel, C., Fawzi, A. A., Schlesinger, T. K., Wong, R. W., Bryan Leung, L. S., Eaton, A. M., Steinle, N. C., Telander, D. G., Afshar, A. R., …, & Stewart, J. M. (2024). METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial. Ophthalmology Science, 4(3), 100440. https://doi.org/10.1016/j.xops.2023.100440

Vancouver

Shen LL, Keenan JD, Chahal N, Taha AT, Saroya J, Ma CJ, et al. METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial. Ophthalmology Science. 2024;4(3):100440. doi:10.1016/j.xops.2023.100440

BibTeX
@article{Shen2024,
  author = {Shen, Liangbo Linus and Keenan, Jeremy D and Chahal, Noor and Taha, Abu Tahir and Saroya, Jasmeet and Ma, Chu Jian and Sun, Mengyuan and Yang, Daphne and Psaras, Catherine and Callander, Jacquelyn and Flaxel, Christina and Fawzi, Amani A and Schlesinger, Thomas K and Wong, Robert W and Bryan Leung, Loh-Shan and Eaton, Alexander M and Steinle, Nathan C and Telander, David G and Afshar, Armin R and Neuwelt, Melissa D and Lim, Jennifer I and Yiu, Glenn and Stewart, Jay M},
  title = {METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial},
  journal = {Ophthalmology Science},
  year = {2024},
  volume = {4},
  number = {3},
  pages = {100440},
  doi = {10.1016/j.xops.2023.100440}
}
Kostenlos starten →